Cargando…
Efficacy and In Vitro Activity of Novel Antibiotics for Infections With Carbapenem-Resistant Gram-Negative Pathogens
Infections by Gram-negative multi-drug resistant (MDR) bacterial species are difficult to treat using available antibiotics. Overuse of carbapenems has contributed to widespread resistance to these antibiotics; as a result, carbapenem-resistant Enterobacterales (CRE), A. baumannii (CRAB), and P. aer...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163340/ https://www.ncbi.nlm.nih.gov/pubmed/35669117 http://dx.doi.org/10.3389/fcimb.2022.884365 |
_version_ | 1784719897009324032 |
---|---|
author | Cruz-López, Flora Martínez-Meléndez, Adrian Morfin-Otero, Rayo Rodriguez-Noriega, Eduardo Maldonado-Garza, Héctor J. Garza-González, Elvira |
author_facet | Cruz-López, Flora Martínez-Meléndez, Adrian Morfin-Otero, Rayo Rodriguez-Noriega, Eduardo Maldonado-Garza, Héctor J. Garza-González, Elvira |
author_sort | Cruz-López, Flora |
collection | PubMed |
description | Infections by Gram-negative multi-drug resistant (MDR) bacterial species are difficult to treat using available antibiotics. Overuse of carbapenems has contributed to widespread resistance to these antibiotics; as a result, carbapenem-resistant Enterobacterales (CRE), A. baumannii (CRAB), and P. aeruginosa (CRPA) have become common causes of healthcare-associated infections. Carbapenems, tigecycline, and colistin are the last resource antibiotics currently used; however, multiple reports of resistance to these antimicrobial agents have been documented worldwide. Recently, new antibiotics have been evaluated against Gram-negatives, including plazomicin (a new aminoglycoside) to treat CRE infection, eravacycline (a novel tetracycline) with in vitro activity against CRAB, and cefiderocol (a synthetic conjugate) for the treatment of nosocomial pneumonia by carbapenem-non-susceptible Gram-negative isolates. Furthermore, combinations of known β-lactams with recently developed β-lactam inhibitors, such as ceftazidime-avibactam, ceftolozane-tazobactam, ceftazidime-tazobactam, and meropenem-vaborbactam, has been suggested for the treatment of infections by extended-spectrum β-lactamases, carbapenemases, and AmpC producer bacteria. Nonetheless, they are not active against all carbapenemases, and there are reports of resistance to these combinations in clinical isolates.This review summarizes and discusses the in vitro and clinical evidence of the recently approved antibiotics, β-lactam inhibitors, and those in advanced phases of development for treating MDR infections caused by Gram-negative multi-drug resistant (MDR) bacterial species. |
format | Online Article Text |
id | pubmed-9163340 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91633402022-06-05 Efficacy and In Vitro Activity of Novel Antibiotics for Infections With Carbapenem-Resistant Gram-Negative Pathogens Cruz-López, Flora Martínez-Meléndez, Adrian Morfin-Otero, Rayo Rodriguez-Noriega, Eduardo Maldonado-Garza, Héctor J. Garza-González, Elvira Front Cell Infect Microbiol Cellular and Infection Microbiology Infections by Gram-negative multi-drug resistant (MDR) bacterial species are difficult to treat using available antibiotics. Overuse of carbapenems has contributed to widespread resistance to these antibiotics; as a result, carbapenem-resistant Enterobacterales (CRE), A. baumannii (CRAB), and P. aeruginosa (CRPA) have become common causes of healthcare-associated infections. Carbapenems, tigecycline, and colistin are the last resource antibiotics currently used; however, multiple reports of resistance to these antimicrobial agents have been documented worldwide. Recently, new antibiotics have been evaluated against Gram-negatives, including plazomicin (a new aminoglycoside) to treat CRE infection, eravacycline (a novel tetracycline) with in vitro activity against CRAB, and cefiderocol (a synthetic conjugate) for the treatment of nosocomial pneumonia by carbapenem-non-susceptible Gram-negative isolates. Furthermore, combinations of known β-lactams with recently developed β-lactam inhibitors, such as ceftazidime-avibactam, ceftolozane-tazobactam, ceftazidime-tazobactam, and meropenem-vaborbactam, has been suggested for the treatment of infections by extended-spectrum β-lactamases, carbapenemases, and AmpC producer bacteria. Nonetheless, they are not active against all carbapenemases, and there are reports of resistance to these combinations in clinical isolates.This review summarizes and discusses the in vitro and clinical evidence of the recently approved antibiotics, β-lactam inhibitors, and those in advanced phases of development for treating MDR infections caused by Gram-negative multi-drug resistant (MDR) bacterial species. Frontiers Media S.A. 2022-05-20 /pmc/articles/PMC9163340/ /pubmed/35669117 http://dx.doi.org/10.3389/fcimb.2022.884365 Text en Copyright © 2022 Cruz-López, Martínez-Meléndez, Morfin-Otero, Rodriguez-Noriega, Maldonado-Garza and Garza-González https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cellular and Infection Microbiology Cruz-López, Flora Martínez-Meléndez, Adrian Morfin-Otero, Rayo Rodriguez-Noriega, Eduardo Maldonado-Garza, Héctor J. Garza-González, Elvira Efficacy and In Vitro Activity of Novel Antibiotics for Infections With Carbapenem-Resistant Gram-Negative Pathogens |
title | Efficacy and In Vitro Activity of Novel Antibiotics for Infections With Carbapenem-Resistant Gram-Negative Pathogens |
title_full | Efficacy and In Vitro Activity of Novel Antibiotics for Infections With Carbapenem-Resistant Gram-Negative Pathogens |
title_fullStr | Efficacy and In Vitro Activity of Novel Antibiotics for Infections With Carbapenem-Resistant Gram-Negative Pathogens |
title_full_unstemmed | Efficacy and In Vitro Activity of Novel Antibiotics for Infections With Carbapenem-Resistant Gram-Negative Pathogens |
title_short | Efficacy and In Vitro Activity of Novel Antibiotics for Infections With Carbapenem-Resistant Gram-Negative Pathogens |
title_sort | efficacy and in vitro activity of novel antibiotics for infections with carbapenem-resistant gram-negative pathogens |
topic | Cellular and Infection Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163340/ https://www.ncbi.nlm.nih.gov/pubmed/35669117 http://dx.doi.org/10.3389/fcimb.2022.884365 |
work_keys_str_mv | AT cruzlopezflora efficacyandinvitroactivityofnovelantibioticsforinfectionswithcarbapenemresistantgramnegativepathogens AT martinezmelendezadrian efficacyandinvitroactivityofnovelantibioticsforinfectionswithcarbapenemresistantgramnegativepathogens AT morfinoterorayo efficacyandinvitroactivityofnovelantibioticsforinfectionswithcarbapenemresistantgramnegativepathogens AT rodrigueznoriegaeduardo efficacyandinvitroactivityofnovelantibioticsforinfectionswithcarbapenemresistantgramnegativepathogens AT maldonadogarzahectorj efficacyandinvitroactivityofnovelantibioticsforinfectionswithcarbapenemresistantgramnegativepathogens AT garzagonzalezelvira efficacyandinvitroactivityofnovelantibioticsforinfectionswithcarbapenemresistantgramnegativepathogens |